93. 原発性胆汁性胆管炎[原発性胆汁性肝硬変 (~2017.3)]
[臨床試験数:230,薬物数:215(DrugBank:51),標的遺伝子数:34,標的パスウェイ数:107

Searched query = "Primary biliary cholangitis", "Primary biliary cirrhosis", "PBC"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
6 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR1800020160
2018-12-202018-12-18Clinical research for fenofibrate in the treatment of refractory primary biliary cirrhosisClinical research for fenofibrate in the treatment of refractory primary biliary cirrhosis Primary Biliary Cirrhosis1:Fenofibrate+UDCA;2:UDCA;Peking Union Medical College HosipitalNULLRecruiting1865Both1:20;2:20;China
2NCT02823353
(ClinicalTrials.gov)
January 201628/1/2016Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary CirrhosisFenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis: a Randomized Control StudyPrimary Biliary CirrhosisDrug: Fenofibrate;Drug: UDCAXijing Hospital of Digestive DiseasesNULLRecruiting18 Years70 YearsBoth200Phase 3China
3NCT02965911
(ClinicalTrials.gov)
January 201615/11/2016Efficacy and Safety of Fenofibrate Combined With UDCA in PBC Patients With an Incomplete Biochemical Response to UDCAA Randomized Controlled Clinical Trial on the Efficacy and Safety of Fenofibrate Combined With Ursodeoxycholic Acid in PBC Patients With an Incomplete Biochemical Response to UDCAPrimary Biliary CirrhosisDrug: Fenofibrate;Drug: UDCABeijing 302 HospitalNULLRecruiting18 Years65 YearsBoth72Phase 1;Phase 2China
4NCT02823366
(ClinicalTrials.gov)
January 201628/1/2016Fenofibrate for Patients With Primary Biliary Cirrhosis Who Had An Inadequate Response to Ursodeoxycholic AcidPrimary Biliary CirrhosisDrug: Fenofibrate;Drug: UDCAXijing Hospital of Digestive DiseasesNULLRecruiting18 Years70 YearsBoth200Phase 3China
5NCT01141296
(ClinicalTrials.gov)
April 20118/6/2010Fenofibrate in Combination With Ursodeoxycholic Acid (UDCA) in Primary Biliary CirrhosisRandomized Controlled Study of Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary CirrhosisPrimary Biliary CirrhosisDrug: fenofibrate;Drug: placeboUniversity of MiamiMayo ClinicWithdrawn21 Years75 YearsBoth0Phase 2United States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT00575042
(ClinicalTrials.gov)
August 200713/12/2007Use of Fenofibrate for Primary Biliary CirrhosisPilot Study of Fenofibrate for Primary Biliary CirrhosisPrimary Biliary CirrhosisDrug: Fenofibrate IDD-P (Insoluble Drug Delivery-Micro Particle)University of FloridaThe PBCers Organization;Shionogi Inc.Completed21 Years75 YearsAll20Phase 2United States